Aberrant hyperactivation of Akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 1940-1946

  Han, Sangyeul ^a   Polizzano, Carolyn ^a   Nielsen, Gunnlaugur P ^a   Hornicek, Francis J ^a   Rosenberg, Andrew E ^a   Ramesh, Vijaya ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CHORDOMA; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

CELL PROLIFERATION; CHORDOMA; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 63449109293     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2364     Document Type: Article

References (38)

1. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol 2007;19: 367-70.
2. Stepanek J, Cataldo SA, Ebersold MJ, et al. Familial chordoma with probable autosomal dominant inheritance. Am J Med Genet 1998;75:335-6.
3. Bhadra AK, Casey AT. Familial chordoma. A report of two cases. J Bone Joint Surg Br 2006;88:634-6.
4. Miozzo M, Dalpra L, Riva P, et al. A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int J Cancer 2000;87:68-72.
5. Kelley MJ, Korczak JF, Sheridan E,Yang X, Goldstein AM, Parry DM. Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33. Am J Hum Genet 2001;69:454-60.
6. Yang XR, Beerman M, Bergen AW, et al. Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs). Int J Cancer 2005;116:487-91.
7. Borgel J, Olschewski H, ReuterT,MiterskiB,Epplen JT. Does the tuberous sclerosis complex include clivus chordoma? A case report. Eur J Pediatr 2001;160:138.
8. Dutton RV, Singleton EB. Tuberous sclerosis: a case report with aortic aneurysm and unusual rib changes. Pediatr Radiol 1975;3:184-6.
9. Schroeder BA, Wells RG, Starshak RJ, Sty JR. Clivus chordoma in a child with tuberous sclerosis: CT and MR demonstration. J Comput Assist Tomogr 1987; 11:195-6.
10. Lountzis NI,Hogarty MD,Kim HJ,Junkins-Hopkins JM. Cutaneous metastatic chordoma with concomitant tuberous sclerosis. J Am Acad Dermatol 2006; 55:S6-10.
11. Storm PB, Magge SN, Kazahaya K, Sutton LN. Cervical chordoma in a patient with tuberous sclerosis presenting with shoulder pain. Pediatr Neurosurg 2007;43:167-9.
12. Lee-Jones L, Aligianis I, Davies PA, et al. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 orTSC2. Genes Chromosomes Cancer 2004;41:80-5.
13. Gomez M. Definition and Criteria for Diagnosis. In: Gomez M, Sampson J, Holtes-Whittemore V, editors. Tuberous sclerosis complex. New York: Oxford University Press; 1999. p. 10-2.
14. SatoT, Seyama K, Fujii H, et al. Mutation analysis of theTSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002;47:20-8.
15. CarsilloT, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex geneTSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000;97:6085-90.
16. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
17. Huang J, Manning BD. TheTSC1 -2 complex: a molecular switchboard controlling cell growth. Biochem J2008;412:179-90.
18. Inoki K, Corradetti MN, Guan KL. Dysregulation of theTSC-mTORpathway in human disease. Nat Genet 2005;37:19-24.
19. Scheil S, Bruderlein S, LiehrT, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001;32:203-11.
20. Han S,Witt RM, SantosTM, Polizzano C, Sabatini BL, Ramesh V. Pam (Protein associated with Myc) functions as an E3 Ubiquitin ligase and regulates TSC/mTORsignaling. Cell Signal 2008;20:1084-91.
21. Han S, SantosTM, Puga A, et al. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 2004;64:812-6.
22. Manning BD,TeeAR, Logsdon MN, BlenisJ,Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002;10:151 -62.
23. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007;25:903-15.
24. Hallor KH, Staaf J, Jonsson G, et al. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridization. Br J Cancer 2008;98: 434-42.
25. Li J, YenC,LiawD,et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275: 1943-7.
26. RisingerJI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
27. Bjornsti MA, Houghton PJ. The TORpathway: a target for cancer therapy. Nat Rev Cancer 2004;4: 335-48.
28. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671 -88.
29. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol 2006;33:607-13.
30. Wienecke R, Fackler I, Linsenmaier U, Mayer K, LichtT, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006;48:e27-9.
31. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51.
32. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression ofastrocytomasin tuberous sclerosis complex. Ann Neurol 2006;59:490-8.
33. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23.
34. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527-34.
35. WitzigTE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23: 5347-56.
36. Neshat MS, Mellinghoff IK,Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98: 10314-9.
37. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-34.
38. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTORinhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8: 249-58.